Absci Corp Files Definitive Proxy Statement for 2024 Annual Meeting
Ticker: ABSI · Form: DEF 14A · Filed: Apr 23, 2024 · CIK: 1672688
| Field | Detail |
|---|---|
| Company | Absci CORP (ABSI) |
| Form Type | DEF 14A |
| Filed Date | Apr 23, 2024 |
| Risk Level | medium |
| Pages | 16 |
| Reading Time | 19 min |
| Key Dollar Amounts | $50, $100 million, $1.235 billion, $1 billion, $0.0001 |
| Sentiment | bullish |
Sentiment: bullish
Topics: Absci Corp, ABSI, DEF 14A, AI Drug Discovery, ABS-101
TL;DR
<b>Absci Corporation filed its 2024 Definitive Proxy Statement, showcasing significant AI-driven progress in drug discovery, including the rapid advancement of its ABS-101 antibody candidate.</b>
AI Summary
Absci Corp (ABSI) filed a Proxy Statement (DEF 14A) with the SEC on April 23, 2024. Absci Corporation filed a Definitive Proxy Statement (DEF 14A) on April 23, 2024. The filing details the company's progress in 2023, highlighting advancements in AI-driven drug discovery. Absci successfully advanced its internal asset program, ABS-101 (anti-TL1A antibody), from conception to candidate phase in 14 months. The company emphasizes its integration of synthetic biology data and wet lab capabilities with generative AI models. Strategic partnerships with industry leaders like AstraZeneca and Almirall are noted as key to enhancing AI capabilities.
Why It Matters
For investors and stakeholders tracking Absci Corp, this filing contains several important signals. The filing provides shareholders with an update on the company's strategic direction and technological achievements, particularly in leveraging AI for drug development. It highlights Absci's efforts to reduce the traditional time, cost, and risk associated with bringing drug candidates from conception to IND, potentially improving R&D economics.
Risk Assessment
Risk Level: medium — Absci Corp shows moderate risk based on this filing. The company's reliance on AI and synthetic biology for drug discovery, while promising, represents a relatively new and evolving field, carrying inherent technological and execution risks.
Analyst Insight
Shareholders should monitor the progress of ABS-101 and the impact of AI integration on future drug development timelines and costs.
Key Numbers
- 14 — months (Time to advance ABS-101 from conception to candidate phase)
- 2023 — year (Period of significant technological and strategic milestones)
- $50 to $100 million — investment range (Estimated investment per asset to IND in pharma industry)
- 5 years — timeline (Traditional timeline to IND application in pharma industry)
Key Players & Entities
- Absci Corp (company) — Registrant name
- ABSI (company) — Ticker symbol
- DEF 14A (document) — Filing type
- 2024-04-23 (date) — Filing date
- Sean McClain (person) — Founder & CEO
- ABS-101 (drug_candidate) — Internal asset program
- AstraZeneca (company) — Strategic partner
- Almirall (company) — Strategic partner
FAQ
When did Absci Corp file this DEF 14A?
Absci Corp filed this Proxy Statement (DEF 14A) with the SEC on April 23, 2024.
What is a DEF 14A filing?
A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by Absci Corp (ABSI).
Where can I read the original DEF 14A filing from Absci Corp?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Absci Corp.
What are the key takeaways from Absci Corp's DEF 14A?
Absci Corp filed this DEF 14A on April 23, 2024. Key takeaways: Absci Corporation filed a Definitive Proxy Statement (DEF 14A) on April 23, 2024.. The filing details the company's progress in 2023, highlighting advancements in AI-driven drug discovery.. Absci successfully advanced its internal asset program, ABS-101 (anti-TL1A antibody), from conception to candidate phase in 14 months..
Is Absci Corp a risky investment based on this filing?
Based on this DEF 14A, Absci Corp presents a moderate-risk profile. The company's reliance on AI and synthetic biology for drug discovery, while promising, represents a relatively new and evolving field, carrying inherent technological and execution risks.
What should investors do after reading Absci Corp's DEF 14A?
Shareholders should monitor the progress of ABS-101 and the impact of AI integration on future drug development timelines and costs. The overall sentiment from this filing is bullish.
Risk Factors
- Reliance on Generative AI and Synthetic Biology [medium — operational]: The company's core strategy relies on the successful integration and advancement of generative AI models with synthetic biology capabilities, which are rapidly evolving fields.
- Capital Intensive Nature of Drug Development [medium — financial]: Developing drug candidates, even with AI acceleration, remains a capital-intensive process with significant financial risks and long development timelines.
- Regulatory Approval Process [medium — regulatory]: Drug candidates must navigate a complex and lengthy regulatory approval process, with no guarantee of success.
Key Dates
- 2024-04-23: Filing of Definitive Proxy Statement — Provides shareholders with an update on company strategy and progress.
Glossary
- Generative AI
- Artificial intelligence capable of creating new content, such as text, images, or drug molecules. (Central to Absci's strategy for accelerating drug discovery and reshaping R&D economics.)
- Synthetic Biology
- The design and construction of new biological parts, devices, and systems, or the re-design of existing, natural biological systems for useful purposes. (Absci integrates this with AI to generate and test novel biologics.)
Filing Stats: 4,783 words · 19 min read · ~16 pages · Grade level 13.2 · Accepted 2024-04-23 16:08:21
Key Financial Figures
- $50 — ates often see investments ranging from $50 to $100 million per asset, with timelin
- $100 million — ten see investments ranging from $50 to $100 million per asset, with timelines stretching mo
- $1.235 billion — gross revenue is equal to or more than $1.235 billion (iii) the date on which we have issued
- $1 billion — date on which we have issued more than $1 billion in nonconvertible debt during the previ
- $0.0001 — 2 shares of our common stock, par value $0.0001 per share, outstanding on April 15, 202
Filing Documents
- proxydefstatement2024annua.htm (DEF 14A) — 613KB
- absci_logoa.jpg (GRAPHIC) — 76KB
- amrit-nagpala.jpg (GRAPHIC) — 234KB
- andreas-buschxchiefxinnovaa.jpg (GRAPHIC) — 208KB
- chart_demographicbackgrouna.jpg (GRAPHIC) — 310KB
- chart_genderidentity2024a.jpg (GRAPHIC) — 115KB
- chart_legendsa.jpg (GRAPHIC) — 40KB
- cover_backa.jpg (GRAPHIC) — 151KB
- cover_front2024a.jpg (GRAPHIC) — 122KB
- dan-rabinovitsja.jpg (GRAPHIC) — 304KB
- employees_1a.jpg (GRAPHIC) — 1539KB
- frans_vanxhoutenxforxproxya.jpg (GRAPHIC) — 169KB
- headshot_forxletter2a.jpg (GRAPHIC) — 3952KB
- joseph-sirosha.jpg (GRAPHIC) — 207KB
- karen-mcginnisa.jpg (GRAPHIC) — 202KB
- labspace_1a.jpg (GRAPHIC) — 1388KB
- mene-pangalos_forxproxya.jpg (GRAPHIC) — 111KB
- photo1absci_hq3a.jpg (GRAPHIC) — 721KB
- proxycard_1a.jpg (GRAPHIC) — 668KB
- proxycard_2a.jpg (GRAPHIC) — 734KB
- scientist_1a.jpg (GRAPHIC) — 916KB
- sean-mcclaina.jpg (GRAPHIC) — 155KB
- sean_signaturexsmootha.jpg (GRAPHIC) — 97KB
- zachariah-jonassona.jpg (GRAPHIC) — 195KB
- 0001628280-24-017379.txt ( ) — 17757KB
Executive Compensation
Executive Compensation 38 Certain Relationships and Related Party Transactions 48 Principal Stockholders 51 Report of the Audit Committee 54 Householding 55 Stockholder Proposals 56 Other Matters 58 Cautionary Note Regarding Forward-Looking Statements 59 Proxy Statement 1 Proxy Statement for the 2024 Annual Meeting of Stockholders to be held June 12, 2024 ABSCI CORPORATION 18105 SE Mill Plain Blvd Vancouver, WA 98683 This proxy statement contains information about the 2024 Annual Meeting of Stockholders, or the Annual Meeting, of Absci Corporation, which will be held online on Wednesday, June 12, 2024 at 900 a.m. Pacific Time. In order to provide access to our stockholders regardless of geographic location and support the health and well-being of our stockholders, employees and communities, this year's Annual Meeting will be held virtually. You will be able to attend the Annual Meeting as well as vote and submit your questions during the live webcast of the meeting by visiting www.virtualshareholdermeeting.comABSI2024 and entering the 16digit control number included in the Notice of Internet Availability of Proxy Materials, on your proxy card or in the instructions that accompanied your proxy materials. The board of directors of Absci Corporation is using this proxy statement to solicit proxies for use at the Annual Meeting. In this proxy statement, the terms "Absci," the "Company," "we," "us," and "our" refer to Absci Corporation. The mailing address of our principal executive offices is Absci Corporation, 18105 SE Mill Plain Blvd, Vancouver, WA 98683. All properly submitted proxies will be voted in accordance with the instructions contained in those proxies. If no instructions are specified, the proxies will be voted in accordance with the recommendation of our board of directors with respect to each of the matters set forth in this proxy statement and the accompanying proxy card. You may revoke your proxy at any time before it is